Email updates

Keep up to date with the latest news and content from Genome Medicine and BioMed Central.

Journal App

google play app store
Highly Accessed Editorial

2012 highlights in translational 'omics

Charles Auffray1*, Timothy Caulfield2, Muin J Khoury3, James R Lupski45, Matthias Schwab67 and Timothy Veenstra8

Author Affiliations

1 CNRS Institute of Biological Sciences, European Institute for Systems Biology & Medicine, Claude Bernard University, Université de Lyon, France

2 Faculty of Law and School of Public Health, 461 Law Centre, University of Alberta, Edmonton, T6G 2H5, Canada

3 Office of Public Health Genomics, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, MS E61, Atlanta, GA 30333, USA

4 Departments of Molecular and Human Genetics and Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA

5 Texas Children's Hospital, Houston, TX 77030, USA

6 Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbach Str. 112, 70367 Stuttgart, Germany

7 Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, 72076 Tübingen, Germany

8 Laboratory of Proteomics and Analytical Technologies, National Cancer Institute at Frederick, Frederick, MD 21702-1201, USA

For all author emails, please log on.

Genome Medicine 2013, 5:10  doi:10.1186/gm414

Published: 31 January 2013

First paragraph (this article has no abstract)

This annual editorial from Genome Medicine's Section Editors highlights the most exciting research from the past year and the potential of these advances for medicine. Last year, we noted that medical 'omics continued its inexorable move towards the clinic; in 2012 it has truly arrived. DNA capture technologies and sequencing continue to lead the way, with implications for human genomics, personalized medicine, pharmacogenomics and drug labeling, public health screening, and public policy already apparent. There have also been technological advances in proteomics and other 'omic approaches, and in the integration of these approaches to provide more informative molecular signatures of health and susceptibility to disease.